+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Ascites - Epidemiology Forecast - 2030

  • ID: 5264916
  • Report
  • January 2021
  • Region: Global
  • 70 pages
  • DelveInsight
This ‘Ascites - Epidemiology Forecast-2030’ report delivers an in-depth understanding of the disease, historical and forecasted Ascites epidemiology in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.

Ascites Understanding

Ascites (hydroperitoneum is a rare synonym) is defined as an abnormal amount of intraperitoneal fluid. Ascites is a condition in which fluid collects in spaces within the abdomen. If severe, ascites may be painful. The problem may keep the patient from moving around comfortably. Fluid may also move into the chest and surround the lungs. This condition can make eating, drinking, and moving around difficult. It can also make it hard to breathe. Ascites can lead to abdominal infections, which may cause kidney failure and can also cause umbilical or inguinal hernias.

Ascites is common in patients with cirrhosis and usually develops when their liver is beginning to fail. The elevation of the pressure in the veins that run through the liver (portal hypertension) and a decrease in liver function due to the scarring on the liver result in the fluid build-up.

Ascites Epidemiology Perspective

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Number of Ascites Cases due to Cirrhosis, Number of Ascites Cases by Malignancies, and Severity-specific Cases of Ascites due to Cirrhosis scenario of Ascites in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2018 to 2030.

Ascites Detailed Epidemiology Segmentation
  • In 2020, the total cases of Ascites due to cirrhosis in the 7MM was 240,730, which is likely to increase by 2030 at a CAGR of 0.61% for the study period (2018-2030).
  • Malignant Ascites cases are calculated from ovarian cancer, stomach cancer, breast cancer, and colorectal cancer. In 2020, The number of cases of Ascites from these cancers was 8,521; 3,538; 12,650; and 10,276, respectively, in the US.
  • According to the publisher’s analysis, in 2020, there were 26,841 and 122,277 cases of Grade I and Grade II & III ascites due to cirrhosis in the United States.
  • Among the EU-5 countries, the highest cases of Ascites due to cirrhosis were found in Germany (20,004), followed by the UK (15,845) and France (11,138). The least cases of Ascites due to cirrhosis were found in Spain (4,904).
  • There were 29,571 cases of ascites due to cirrhosis in Japan in 2020.
Scope of the Report
  • The report covers the descriptive overview of Ascites, explaining its causes, signs, and symptoms, and pathophysiology.
  • The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan.
  • The report assesses the disease risk and burden.
  • The report provides the segmentation of the disease epidemiology for 7MM by Number of Ascites Cases due to Cirrhosis, Number of Ascites Cases by Malignancies, and Severity-specific Cases of Ascites due to Cirrhosis.
Report Highlights
  • 10-Year Forecast of Ascites
  • 7MM Coverage
  • Number of Ascites Cases due to Cirrhosis
  • Number of Ascites Cases by Malignancies
  • Severity-specific Cases of Ascites due to Cirrhosis
Key Questions Answered
  • What are the disease risk, burdens, and unmet needs of Ascites?
  • What is the historical Ascites patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
  • What would be the forecasted patient pool of Ascites at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Ascites?
  • Out of the countries mentioned above, which country would have the highest patient population of Ascites during the forecast period (2021-2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2021-2030)? 
Reasons to Buy

The Ascites report will allow the user to -
  • Develop business strategies by understanding the trends shaping and driving the 7MM Ascites Epiodemiology.
  • Organize sales and marketing efforts by identifying the specific type of Ascites that presents the best opportunities for Ascites therapeutics in each of the markets covered.
  • The Ascites epidemiology report and model were written and developed by Masters and PhD level epidemiologists.
  • The Ascites epidemiology model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 10-year forecast period using reputable sources.
Key Assessments
  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population
Geographies Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
Study Period: 2018-2030
Note: Product cover images may vary from those shown
1 Key Insights

2 Report Introduction

3 Ascites Epidemiology Overview at a Glance
3.1. Epidemiology Share (%) Distribution of Ascites due to Cirrhosis in 2018
3.2. Epidemiology Share (%) Distribution of Ascites due to Cirrhosis in 2030

4 Executive Summary of Ascites

5 Disease Background and Overview
5.1. Introduction
5.2. Types of ascites and underlying primary diseases
5.3. Causes of Ascites
5.4. Symptoms of Ascites
5.5. Pathogenesis of Ascites
5.6. Diagnosis of Ascites
5.6.1. History
5.6.2. Physical examination
5.6.3. Blood tests
5.6.4. Abdominal ultrasound
5.6.5. Abdominal paracentesis
5.6.6. Visual inspection
5.6.7. Biochemical testing
5.6.8. Nonbiochemical testing
5.6.9. Diagnostic Algorithm
5.7. Diagnostic Guidelines of Ascites
5.7.1. British Society of Gastroenterology and the British Association for the Study of the Liver Guidelines
5.7.2. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis
5.7.3. American Association for the Study of Liver Diseases (AASLD) Management of Adult Patients with Ascites Due to Cirrhosis: Update 2012

6 Epidemiology and Patient Population
6.1. Key Findings
6.2. Methodology for the Epidemiology of Ascites
6.3. Total Cases of Ascites due to Cirrhosis in the 7MM
6.4. Epidemiology of Ascites
6.5. The United States
6.5.1. Number of Ascites Cases due to Cirrhosis in the US
6.5.2. Number of Ascites Cases by Malignancies in the US
6.5.3. Severity-specific Cases of Ascites due to Cirrhosis in the US
6.6. EU5
6.6.1. Germany
6.6.1.1. Number of Ascites Cases due to Cirrhosis in Germany
6.6.1.2. Number of Cases of Ascites by Malignancies in Germany
6.6.1.3. Severity-specific Cases of Ascites due to Cirrhosis in Germany
6.6.2. France
6.6.2.1. Number of Cases of Ascites due to Cirrhosis in France
6.6.2.2. Number of Cases of Ascites by Malignancies in France
6.6.2.3. Severity-specific Cases of Ascites due to Cirrhosis in France
6.6.3. Italy
6.6.3.1. Number of Cases of Ascites due to Cirrhosis in Italy
6.6.3.2. Number of Cases of Ascites by Malignancies in Italy
6.6.3.3. Severity-specific Cases of Ascites due Cirrhosis in Italy
6.6.4. Spain
6.6.4.1. Number of Cases of Ascites due to Cirrhosis in Spain
6.6.4.2. Number of Cases of Ascites by Malignancies in Spain
6.6.4.3. Severity-specific Cases of Ascites due to Cirrhosis in Spain
6.6.5. United Kingdom
6.6.5.1. Number of Ascites Cases due to Cirrhosis in the United Kingdom
6.6.5.2. Number of Cases of Ascites by Malignancies in the United Kingdom
6.6.5.3. Severity-specific Cases of Ascites due to Cirrhosis in the United Kingdom
6.7. Japan
6.7.1. Number of Cases of Ascites due to Cirrhosis in Japan
6.7.2. Number of Cases of by Malignancies in Japan
6.7.3. Severity-specific Cases of Ascites due to Cirrhosis in Japan

7 KOL Views

8 Appendix
8.1. Bibliography
8.2. Report Methodology

9 Publisher Capabilities

10 Disclaimer

11 About the Publisher

List of Tables
Table 1 Summary of Ascites, Epidemiology, and Key Events (2018-2030)
Table 2 Types of ascites and underlying primary diseases
Table 3 Grouping of etiology of ascites based on serum albumin ascites gradient (SAAG)
Table 4 Level of Evidence
Table 5 Grade of recommendations
Table 6 Grading system for recommendations
Table 7 Grade of Ascites and Management Strategy
Table 8 Total Cases of Ascites due to Cirrhosis in the 7MM (2018-2030)
Table 9 Number of Ascites Cases due to Cirrhosis in the United States (2018-2030)
Table 10 Number of Ascites Cases by Malignancies in the United States (2018-2030)
Table 11 Severity-specific Cases of Ascites due to Cirrhosis in the United States (2018-2030)
Table 12 Number of Ascites Cases due to Cirrhosis in Germany (2018-2030)
Table 13 Number of Ascites Cases by Malignancies in Germany (2018-2030)
Table 14 Severity-specific Cases of Ascites due to Cirrhosis in Germany (2018-2030)
Table 15 Number of Ascites Cases due to Cirrhosis in France (2018-2030)
Table 16 Number of Cases of Ascites by Malignancies in France (2018-2030)
Table 17 Severity-specific Cases of Ascites due to Cirrhosis in France (2018-2030)
Table 18 Number of Ascites Cases due to Cirrhosis in Italy (2018-2030)
Table 19 Number of Cases of Ascites by Malignancies in Italy (2018-2030)
Table 20 Severity-specific Cases of Ascites due to Cirrhosis in Italy (2018-2030)
Table 21 Number of Ascites Cases due to Cirrhosis in Spain (2018-2030)
Table 22 Number of Cases of Ascites by Malignancies in Spain (2018-2030)
Table 23 Severity-specific Cases of Ascites due to Cirrhosis in Spain (2018-2030)
Table 24 Number of Ascites Cases due to Cirrhosis in the UK (2018-2030)
Table 25 Number of Cases of Ascites by Malignancies in the United Kingdom (2018-2030)
Table 26 Severity-specific Cases of Ascites due to Cirrhosis in the United Kingdom (2018-2030)
Table 27 Number of Ascites Cases due to Cirrhosis in Japan (2018-2030)
Table 28 Number of Cases of Ascites by Malignancies in Japan (2018-2030)
Table 29 Severity-specific Cases of Ascites due to Cirrhosis in Japan (2018-2030)

List of Figures
Figure 1 Ascites
Figure 2 Causes of Ascites
Figure 3 Symptoms of Ascites
Figure 4 Pathogenesis of ascites formation in the cirrhotic patient.
Figure 5 Diagnostic Approach to the patient with ascites
Figure 6 Diagnostic algorithm of ascites
Figure 7 Total Cases of Ascites due to Cirrhosis in the 7MM (2018-2030)
Figure 8 Number of Ascites Cases due to Cirrhosis in the United States (2018-2030)
Figure 9 Number of Ascites Cases by Malignancies in the United States (2018-2030)
Figure 10 Severity-specific Cases of Ascites due to Cirrhosis in the United States (2018-2030)
Figure 11 Number of Ascites Cases due to Cirrhosis in Germany (2018-2030)
Figure 12 Number of Ascites Cases By Malignancies in Germany (2018-2030)
Figure 13 Severity-specific Cases of Ascites due to Cirrhosis in Germany (2018-2030)
Figure 14 Number of Ascites Cases due to Cirrhosis in France (2018-2030)
Figure 15 Number of Cases of Ascites By Malignancies in France (2018-2030)
Figure 16 Severity-specific Cases of Ascites due to Cirrhosis in France (2018-2030)
Figure 17 Number of Ascites Cases due to Cirrhosis in Italy (2018-2030)
Figure 18 Number of Cases of Ascites by Malignancies in Italy (2018-2030)
Figure 19 Severity-specific Cases of Ascites due to Cirrhosis in Italy (2018-2030)
Figure 20 Number of Ascites Cases due to Cirrhosis in Spain (2018-2030)
Figure 21 Number of Cases of Ascites by Malignancies in Spain (2018-2030)
Figure 22 Severity-specific Cases of Ascites due to Cirrhosis in Spain (2018-2030)
Figure 23 Number of Ascites Cases due to Cirrhosis in the United Kingdom (2018-2030)
Figure 24 Number of Cases of Ascites by Malignancies in the United Kingdom (2018-2030)
Figure 25 Severity-specific Cases of Ascites due to Cirrhosis in the United Kingdom (2018-2030)
Figure 26 Number of Ascites Cases due to Cirrhosis in Japan (2018-2030)
Figure 27 Number of Cases of by Malignancies in Japan (2018-2030)
Figure 28 Severity-specific Cases of Ascites due to Cirrhosis in Japan (2018-2030)
Note: Product cover images may vary from those shown
Adroll
adroll